Reported muscle symptoms during statin treatment amongst Italian dyslipidaemic patients in the real-life setting: the PROSISA Study

Maurizio Averna, Maurizio Averna, Antonina Giammanco, Patrizia Suppressa, Pierandrea Vinci, Giuliana Mombelli, Giuseppe Mandraffino, Antonina Giammanco, Giovanni Battista Vigna, Francesca Savarino, Manuela Casula, Giovanna Squiccimarro, Giancarla Meregalli, Roberto Scicali, Chiara Pavanello, Riccardo Sarzani, Graziana Lupattelli, Chiara Di Pentima, Giuliana Fortunato, Lorenzo Maria VigoSergio D’Addato, Andrea Pasta, Veronica Zampoleri, Chiara Maneschi, Maurizio Averna, Gazzotti, Vito Gandolfo, Angela Colangiulo, Oimastroni, Bonaiti, Marcello Arca, Linda Ramadori, Lorenzo Previato, Maurizio Averna, Linda Ramadori, Josè Pablo Werba, Livia Pisciotta, Maria Grazia Zenti, Lorenzo Previato, Sabina Zambon, Maria Del Ben, Francesco Purrello, Francesco Cipollone, Anna Montali, Adriana Branchi, Franco Cavalot, Anna Maria Fiorenza, Carlo Sabbà, Gianni Biolo, Maurizio Averna, Francesco Angelico, Paolo Rubba, Alberico Luigi Catapano, Alberto Zambon, Marcello Arca, Antonio Carlo Bossi, Emanuela Colombo, Claudio Borghi, Marco Bucci, Liliana Grigore

Risultato della ricerca: Articlepeer review

2 Citazioni (Scopus)

Abstract

Aim: Statin-associated muscle symptoms (SAMS) are a major determinant of poor treatment adherence and/or discontinuation, but a definitive diagnosis of SAMS is challenging. The PROSISA study was an observational retrospective study aimed to assess the prevalence of reported SAMS in a cohort of dyslipidaemic patients. Methods: Demographic/anamnestic data, biochemical values and occurrence of SAMS were collected by 23 Italian Lipid Clinics. Adjusted logistic regression was performed to estimate odds ratio (OR) and 95% confidence intervals for association between probability of reporting SAMS and several factors. Results: Analyses were carried out on 16 717 statin-treated patients (mean ± SD, age 60.5 ± 12.0 years; 52.1% men). During statin therapy, 9.6% (N = 1599) of patients reported SAMS. Women and physically active subjects were more likely to report SAMS (OR 1.23 [1.10–1.37] and OR 1.35 [1.14–1.60], respectively), whist age ≥ 65 (OR 0.79 [0.70–0.89]), presence of type 2 diabetes mellitus (OR 0.62 [0.51–0.74]), use of concomitant nonstatin lipid-lowering drugs (OR 0.87 [0.76–0.99]), use of high-intensity statins (OR 0.79 [0.69–0.90]) and use of potential interacting drugs (OR 0.63 [0.48–0.84]) were associated with lower probability of reporting SAMS. Amongst patients reporting SAMS, 82.2% underwent dechallenge (treatment interruption) and/or rechallenge (change or restart of statin therapy), with reappearance of muscular symptoms in 38.4% (3.01% of the whole cohort). Conclusions: The reported prevalence of SAMS was 9.6% of the whole PROSISA cohort, but only a third of patients still reported SAMS after dechallenge/rechallenge. These results emphasize the need for a better management of SAMS to implement a more accurate diagnosis and treatment re-evaluation.
Lingua originaleEnglish
Numero di pagine13
RivistaJournal of Internal Medicine
Stato di pubblicazionePublished - 2020

All Science Journal Classification (ASJC) codes

  • ???subjectarea.asjc.2700.2724???

Fingerprint

Entra nei temi di ricerca di 'Reported muscle symptoms during statin treatment amongst Italian dyslipidaemic patients in the real-life setting: the PROSISA Study'. Insieme formano una fingerprint unica.

Cita questo